Literature DB >> 22522456

STEAP proteins: from structure to applications in cancer therapy.

Inês M Gomes1, Cláudio J Maia, Cecília R Santos.   

Abstract

The human 6-transmembrane epithelial antigen of prostate (STEAP) family comprises STEAP1, STEAP2, STEAP3, and STEAP4. All of these proteins are unique to mammals and share an innate activity as metalloreductases, indicating their importance in metal metabolism. Overall, they participate in a wide range of biologic processes, such as molecular trafficking in the endocytic and exocytic pathways and control of cell proliferation and apoptosis. STEAP1 and STEAP2 are overexpressed in several types of human cancers, namely prostate, bladder, colon, pancreas, ovary, testis, breast, cervix, and Ewing sarcoma, but their clinical significance and role in cancer cells are not clear. Still, their localization in the cell membrane and differential expression in normal and cancer tissues make STEAP proteins potential candidates as biomarkers of several cancers, as well as potential targets for new immunotherapeutic strategies for disease attenuation or treatment. This review brings together the current knowledge about each STEAP protein, giving an overview of the roles of this family of proteins in human physiology and disease, and analyzes their potential as immunotherapeutic agents in cancer research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522456     DOI: 10.1158/1541-7786.MCR-11-0281

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  66 in total

1.  Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.

Authors:  William K C Cheung; Minghui Zhao; Zongzhi Liu; Laura E Stevens; Paul D Cao; Justin E Fang; Thomas F Westbrook; Don X Nguyen
Journal:  Cancer Cell       Date:  2013-05-23       Impact factor: 31.743

2.  Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

Authors:  Joseph A O'Donoghue; Daniel C Danila; Neeta Pandit-Taskar; Volkan Beylergil; Sarah M Cheal; Stephen E Fleming; Josef J Fox; Shutian Ruan; Pat B Zanzonico; Govind Ragupathi; Serge K Lyashchenko; Simon P Williams; Howard I Scher; Bernard M Fine; John L Humm; Steven M Larson; Michael J Morris; Jorge A Carrasquillo
Journal:  Mol Pharm       Date:  2019-05-31       Impact factor: 4.939

Review 3.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

4.  STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.

Authors:  Qing Yang; Guoxin Ji; Jiyu Li
Journal:  Cancer Biol Ther       Date:  2019-11-07       Impact factor: 4.742

5.  Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders.

Authors:  Yun Liang; Xianying Xing; Maria A Beamer; William R Swindell; Mrinal K Sarkar; Liza Wolterink Roberts; John J Voorhees; J Michelle Kahlenberg; Paul W Harms; Andrew Johnston; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2016-11-21       Impact factor: 10.793

6.  Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.

Authors:  Inês Margarida Gomes; Sandra Moreira Rocha; Carlos Gaspar; Maria Inês Alvelos; Cecília Reis Santos; Sílvia Socorro; Cláudio Jorge Maia
Journal:  Med Oncol       Date:  2018-02-20       Impact factor: 3.064

7.  Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Daniel C Danila; Russell Z Szmulewitz; Ulka Vaishampayan; Celestia S Higano; Ari D Baron; Houston N Gilbert; Flavia Brunstein; Marija Milojic-Blair; Bei Wang; Omar Kabbarah; Michael Mamounas; Bernard M Fine; Daniel J Maslyar; Alexander Ungewickell; Howard I Scher
Journal:  J Clin Oncol       Date:  2019-11-05       Impact factor: 44.544

8.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Authors:  Jorge A Carrasquillo; Bernard M Fine; Neeta Pandit-Taskar; Steven M Larson; Stephen E Fleming; Josef J Fox; Sarah M Cheal; Joseph A O'Donoghue; Shutian Ruan; Govind Ragupathi; Serge K Lyashchenko; John L Humm; Howard I Scher; Mithat Gönen; Simon P Williams; Daniel C Danila; Michael J Morris
Journal:  J Nucl Med       Date:  2019-05-03       Impact factor: 10.057

9.  Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Authors:  Matthew J Atherton; Kyle B Stephenson; Fanny Tzelepis; David Bakhshinyan; Jake K Nikota; Hwan Hee Son; Anna Jirovec; Charles Lefebvre; Anna Dvorkin-Gheva; Ali A Ashkar; Yonghong Wan; David F Stojdl; Eric C Belanger; Rodney H Breau; John C Bell; Fred Saad; Sheila K Singh; Jean-Simone Diallo; Brian D Lichty
Journal:  Oncoimmunology       Date:  2018-03-27       Impact factor: 8.110

10.  The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.

Authors:  Melissa S Simper; Joyce E Rundhaug; Carol Mikulec; Rebecca Bowen; Jianjun Shen; Yue Lu; Kevin Lin; Inok Surh; Susan M Fischer
Journal:  Mol Oncol       Date:  2014-07-03       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.